Recent studies on anti-PD1 monotherapy have demonstrated that CXCL9 and CXCL10 were crucial, since its receptor CXCR3 was found to be the arbitrator for the PD-1+ CD8+ T cells infiltration in B16 murine melanoma tumours (141). Here, CXCL9 is linked to neoplasm.